Sanofi paying big for FDA voucher; Retrophin snags $245m
This article was originally published in Scrip
Executive Summary
It didn't take Retrophin long to find a buyer for the FDA priority review voucher it snapped up in March when it exercised its rights to purchase the newly approved Cholbam (cholic acid) from Asklepion Pharmaceuticals for $27m plus 661,278 shares of the former firm's common stock.
You may also be interested in...
1Q Earnings Preview: What To Expect From US, EU Big Hitters
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.